Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
-
Shares outstanding
-
266,212,950
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
178,106,548
-
Shares change
-
+2,530,863
-
Total reported value, excl. options
-
$619,765,055
-
Value change
-
-$54,511,638
-
Put/Call ratio
-
57%
-
Number of buys
-
54
-
Number of sells
-
51
-
Price
-
$3.48
Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) as of Q2 2024
As of 30 Jun 2024 Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) had 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 178,106,548 shares of stock of the company.
Largest 10 holders included Syncona Portfolio Ltd, Blackstone Inc., WELLINGTON MANAGEMENT GROUP LLP, Deep Track Capital, LP, Avoro Capital Advisors LLC, FMR LLC, TFG Asset Management GP Ltd, ARMISTICE CAPITAL, LLC, Frazier Life Sciences Management, L.P., and BlackRock Inc..
This table shows 136 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.